Study finds hydroxychloroquine delays disability for least treatable form of multiple sclerosis

A University of Calgary study has found promising results for the generic drug hydroxychloroquine when used to treat the evolution of disability of primary progressive multiple sclerosis (MS), the least treatable form of the autoimmune disease.

Related Keywords

Canada ,Canadians ,Marcus Koch ,Cumming School Of Medicine ,Hotchkiss Brian Institute ,Ba University Of Calgary ,Department Of Clinical Neurosciences ,Clinical Neurosciences ,Study ,Kinds ,Hydroxychloroquine ,Delays ,Disability ,Or ,Least ,Untreatable ,Form ,F ,Multiple ,Clerosis ,News ,Ews India ,